MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo

Cancer Biology and Therapy

Volumn 16, Issue 2, 2015, Pages 261-267

  Peng, Xiaowei ^a   Cao, Peiguo ^b   Li, Jingjing ^b   He, Dong ^c   Han, Shuang ^b   Zhou, Jianda ^b   Tan, Guolin ^b   Li, Wei ^b   Yu, Fenghui ^b   Yu, Jianjun ^a   Li, Zan ^a   Cao, Ke ^b  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Second People's Hospital of Hunan Province   (China)

Author keywords

Chemotherapy; microRNAs; miR 1204; Nasopharyngeal carcinoma; Paclitaxel

Indexed keywords

MICRORNA; MICRORNA 1204; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN-1204 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER GENE THERAPY; CANCER INHIBITION; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; UPREGULATION; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; NASOPHARYNX TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924630850     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2014.1001287     Document Type: Article

References (28)

1. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988; 42:329-38; PMID:2843473; http://dx.doi.org/10.1002/ijc.2910420305
2. Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a "Cantonese cancer"? Chin J Cancer 2010; 29:517-26; PMID:20426903; http://dx.doi.org/10.5732/cjc.009.10329
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-65; PMID:15057285; http://dx.doi.org/10.1038/nrc1317
4. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann Rev Med 1997; 48:353-74; PMID:9046968; http://dx.doi.org/10.1146/annurev.med.48.1.353
5. He XY, Hu CS, Ying HM, Wu YR, Zhu GP, Liu TF. Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Eur Arch Oto-Rhino-Laryngol 2010; 267:773-8; PMID:19820959; http://dx.doi.org/10.1007/s00405-009-1112-7
6. Leong SS, Wee J, Rajan S, Toh CK, Lim WT, Hee SW, Tay MH, Poon D, Tan EH. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer 2008; 113:1332-7; PMID:18615622; http://dx.doi.org/10.1002/cncr.23687
7. Leong SS, Wee J, Tay MH, Toh CK, Tan SB, Thng CH, Foo KF, Lim WT, Tan T, Tan EH. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. Cancer 2005; 103:569-75; PMID:15611975; http://dx.doi.org/10.1002/cncr.20804
8. Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, Chua ET, Tan T, Khoo-Tan HS, Yang TL, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999; 10:235-7; PMID: 10093695; http://dx.doi.org/10.1023/A:1008390929826
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045-5
10. Li M, Li J, Ding X, He M, Cheng SY. microRNA and cancer. AAPS J 2010; 12:309-17; PMID:20422339; http://dx.doi.org/10.1208/s12248-010-9194-0
11. Raza U, Zhang JD, Sahin O. MicroRNAs: master regulators of drug resistance, stemness, and metastasis. J Mol Med 2014; 92:321-36; PMID:24509937; http://dx.doi.org/10.1007/s00109-014-1129-2
12. Cai J, Yang C, Yang Q, Ding H, Jia J, Guo J, Wang J, Wang Z. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis 2013; 2:e75; PMID:24100610; http://dx.doi.org/10.1038/oncsis.2013.39
13. -2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat 2014; 13:77-86; PMID:23862748
14. Chen J, Fu X, Wan Y, Wang Z, Jiang D, Shi L. miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol 2014; 35(7):6293-302; PMID:24643683; http://dx.doi.org/10.1007/s13277-014-1821-4
15. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011; 286:19127-37; PMID:21471222; http://dx.doi.org/10.1074/jbc.M110.216887
16. Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, Parissenti A, Duan Z, Voest EE, Zetter BR. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011; 30:4386-98; PMID:21552288; http://dx.doi.org/10.1038/onc.2011.148
17. Shen Y, Wang P, Li Y, Ye F, Wang F, Wan X, Cheng X, Lu W, Xie X. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. British J Cancer 2013; 109:92-9; PMID:23778521; http://dx.doi.org/10.1038/bjc.2013.308
18. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009; 8:1055-66; PMID:19435871; http://dx.doi.org/10.1158/1535-7163.MCT-08-1046
19. -2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010; 285:21496-507; PMID:20460378; http://dx.doi.org/10.1074/jbc.M109.083337
20. Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY, Kang CS. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010; 10:27; PMID:20113523; http://dx.doi.org/10.1186/1471-2407-10-27
21. Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R, Schageman JJ, Greer R, Yang CR, Suraokar M, et al. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PloS one 2012; 7:e39167; PMID:22723956; http://dx.doi.org/10.1371/journal.pone.0039167
22. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010; 285:19076-84; PMID:20406806; http://dx.doi.org/10.1074/jbc.M109.079525
23. Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, Mahato RI. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PloS one 2012; 7:e40021; PMID:22768203; http://dx.doi.org/10.1371/journal.pone.0040021
24. Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin SE, Mushinski JF, Stephens R, Caplen NJ. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res 2008; 6:212-21; PMID:18314482; http://dx.doi.org/10.1158/1541-7786.MCR-07-0105
25. Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C. p53-Dependent induction of PVT1 and miR-1204. J Biol Chem 2012; 287: 2509-19; PMID:22110125; http://dx.doi.org/10.1074/jbc.M111.322875
26. Marasa BS, Srikantan S, Martindale JL, Kim MM, Lee EK, Gorospe M, Abdelmohsen K. MicroRNA profiling in human diploid fibroblasts uncovers miR-519 role in replicative senescence. Aging 2010; 2:333-43; PMID:20606251
27. Bisio A, De Sanctis V, Del Vescovo V, Denti MA, Jegga AG, Inga A, Ciribilli Y. Identification of new p53 target microRNAs by bioinformatics and functional analysis. BMC Cancer 2013; 13:552; PMID:24256616; http://dx.doi.org/10.1186/1471-2407-13-552
28. Peng X, Li W, Tan G. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. Anti-Cancer Drugs 2010; 21:381-8; PMID:20051827; http://dx.doi.org/10.1097/CAD.0b013e3283363980